Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101) | Zendy

N. Steele | Zendy; Jane A. Plumb | Zendy; Laura Vidal | Zendy; Jette Tjørnelund | Zendy; Poul Knoblauch | Zendy; P. Buhl-Jensen | Zendy; R. Molife | Zendy; Robert Brown | Zendy; Johann S. de Bono | Zendy; T. R. J. Evans | Zendy

Open Access

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

Author(s) -

N. Steele,

Jane A. Plumb,

Laura Vidal,

Jette Tjørnelund,

Poul Knoblauch,

P. Buhl-Jensen,

R. Molife,

Robert Brown,

Johann S. de Bono,

T. R. J. Evans

Publication year - 2010

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-010-1419-5

Subject(s) - pharmacokinetics , histone deacetylase inhibitor , pharmacology , pharmacodynamics , histone deacetylase , medicine , chemistry , histone , biochemistry , dna

The primary objective of this sub-study, undertaken as an extension to the previously reported phase-I study, was to explore the feasibility, tolerability and pharmacokinetics (PK) of belinostat when administered by the oral route. Preliminary pharmacodynamic (PD) studies were also performed to enable comparison of the biological effects of the oral and intravenous formulations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research